Boston-based Alexion Pharmaceuticals announced positive topline data from the company’s Phase III trial of Ultomiris (ravulizumab-cwvz) in adults with generalized myasthenia gravis.
The U.S. FDA gave Alexion Pharmaceuticals a thumbs-up for Soliris (eculizumab) to treat neuromyelitis optica spectrum disorder in adults that express a specific biomarker.
The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
Although the stock market seems to be moving up at the beginning of this year, the U.S. equities market appears more mixed, with healthcare stocks in particular appearing more volatile.
Alexion Pharmaceuticals Inc. announced that the MHLW in Japan approved Soliris (eculizumab) as a treatment for patients with generalized myasthenia gravis.
The U.S. Food and Drug Administration expanded the approval for Alexion Pharmaceuticals Inc.’s blood-disorder drug and blockbuster medicine Soliris.